Carl Zeiss Meditec Investor Relations

Carl Zeiss Meditec AG wins patent infringement action on trifocal intraocular lens against VSY Biotechnology and Fritz Ruck Ophthalmologische Systeme GmbH Carl Zeiss Meditec AG has won a patent infringement action before the District Court of Düsseldorf/Germany against VSY Biotechnology BV and its exclusive distribution partner Fritz Ruck Ophthalmologische Systeme GmbH. Carl Zeiss Meditec AG : He is responsible for Finance and Controlling, Investor Relations, and Legal and Taxes. 9% (adjusted for currency effects: +8. In financial year 2012/2013 (ended 30 September) the Group's more than 2,500 employees generated revenue of almost € 906 million. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Carl Zeiss Meditec AG is a subsidiary of Carl Zeiss AG. Ludwin Monz, President and CEO of Carl Zeiss Meditec. Contact for investors and press Sebastian Frericks Director Investor Relations Carl Zeiss Meditec AG Tel. The Management Board and Supervisory Board of Carl Zeiss Meditec AG hereby declare, pursuant to Section 161 (1) Sentence 1 AktG, that since issuing its last Declaration of Conformity on 7 December 2017, Carl Zeiss Meditec AG has conformed and does conform to all recommendations of the Government Commission on the German Corporate Governance Code, as published by the German Federal Ministry of. Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. Processed and transmitted by Thomson Reuters ONE. We welcome you to Carl Zeiss Meditec AG's Investor Relations website and thank you for your interest in our company. DGAP-Adhoc: Carl Zeiss Meditec AG erzielt deutliche Zuwächse bei Umsatz und Ergebnis im Geschäftsjahr 2018/19 - Nachrichtendetails | Börse München. Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. The Carl Zeiss Meditec Group has operations all over the world. The "Bookmarks" tab. Carl Zeiss Meditec is aiming for the upper end of its revenue forecast for the current year and expects strong earnings : Jena, July 15, 2019 Carl Zeiss Meditec (ISIN: DE0005313704) has achieved. DGAP Voting Rights Announcement Carl Zeiss Meditec AG Carl Zeiss Meditec AG Release according to Article 40 Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europewide. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. Schallhorn, MD As Chief Medical Officer - read this article along with other careers information, tips and advice on BioSpace. The head office of Carl Zeiss Meditec is in Jena, Germany. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. : +49 3641 220-106. Carl Zeiss Meditec Unternehmensprofil: Hier finden Sie die Unternehmensprofil-Seite für den Wert Carl Zeiss Meditec. With its head-quarters in Jena (Germany) and additional plants and subsidiaries in Germany, France, Spain, the USA and Japan, the Company has a direct presence in the world's most important medical technology markets. Processed and transmitted by Thomson Reuters ONE. JENA - 18 January 2010. Find a variety of Carl Zeiss Meditec AG statistics including live AFX. footnote_1 Ansprechpartner für Investoren und Presse Sebastian Frericks Director Investor Relations Carl Zeiss Meditec AG Tel. Regulatory News: Notification pursuant to Article 26 Section 1 of WpHG, intended for Europe-wide publication Legg Mason & Co (UK) Limited, London, Great Britain, informed Carl Zeiss Meditec AG, Jena, Germany, on 8 May 2012 pursuant to Art. Carl Zeiss Meditec AG (OTCPK:CZMWF) Q3 2016 Earnings Conference Call August 12, 2016 3:30 AM ET Executives Sebastian Frericks - Director of Investor Relations Ludwin Monz - President and Chief. Carl Zeiss Meditec AG ADR. 51-52, Jena, Thüringen, Germany - Yelp. DGAP-News: Carl Zeiss Meditec im Geschäftsjahr 2017/18 weiterhin auf Wachstumskurs. Carl Zeiss Meditec AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution. The Company supplies innovative technologies and. [email protected] com [1] Das. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. CH - key executives, insider trading, ownership, revenue and average growth rates. in recognition of achieving excellence in customer service in. View the latest news on CZMWF company insiders for best stock investing positioning. Carl Zeiss Meditec AG resolves on a cash capital increase of up to 10 percent. Carl Zeiss Meditec AG / Carl Zeiss Meditec AG : Carl Zeiss Meditec improves its results in first six months of financial year 2012/2013. Herzlich willkommen auf der Investor Relations Seite der Carl Zeiss Meditec AG. Carl Zeiss Meditec ist auf Produktion und Vermarktung von Systemen und Materialien zur Augendiagnose spezialisiert. Ludwin Monz, President and CEO of Carl Zeiss Meditec. 9 million), based on preliminary data, and has thereby. The issuer is. , and their affiliates (collectively CZM) were informed yesterday that a suit has been filed by IntraLase Corporation. Pursuant to Section 161 AktG the Management and Supervisory Boards of Carl Zeiss Meditec AG are obliged to submit an annual declaration stating that the recommendations of the "Government Commission on the German Corporate Governance Code" have been complied with. If you want to stay up-to-date about the latest developments of Carl Zeiss Meditec Group, there is no faster way. Copyright ® 2019 Henry Schein, Inc. : +49 3641 220-116 E-Mail: investors. Carl Zeiss Meditec announced today that it has received the NorthFace ScoreBoard (NFSB) Award SM from the Omega Management Group Corp. Carl Zeiss Meditec to acquire Laser Diagnostic Technologies Acquisition complements product portfolio and makes Carl Zeiss Meditec the undisputed market leader in the growth market of glaucoma diagnosis and management Dublin, CA - Jena, Germany, October 21, 2004 – Carl Zeiss Meditec, Inc. See how we value this stock with expert insights and research. 9% (adjusted for currency effects: +8. Carl Zeiss Meditec AG is a subsidiary of Carl Zeiss AG. Once again, Carl Zeiss Meditec has set itself ambitious targets for fiscal year 2017/18. Carl Zeiss Meditec Recruits James V. The Carl Zeiss Meditec Group has operations all over the world. The company was founded in 2002 and is headquartered in Jena, Germany. In financial year 2012/2013 (ended 30 September) the Group's more than 2,500 employees generated revenue of almost € 906 million. : +49 3641 220-116 E-Mail: investors. Latest surgical microscope for the ophthalmic surgeon impresses not only users, but also designers. It was founded by Ernst Abbe in 1889 and named after his long-term partner Carl Zeiss. Carl Zeiss Meditec AG berichtet weiteres Wachstum und konkretisiert Prognose für Geschäftsjahr 2018/19 ^ DGAP-Ad-hoc: Carl Zeiss Meditec AG / Schlagwort(e. Working within medicine is a true privilege. DGAP-News: Carl Zeiss Meditec AG / Key word(s): 9-month figures Carl Zeiss Meditec accelerates growth 10. , and their affiliates (collectively CZM) were informed yesterday that a suit has been filed by IntraLase Corporation. View profile. Mazzo will join Carl Zeiss Meditec as Global President of Ophthalmology with responsibility for the new Strategic Business Unit Ophthalmology as well as Carl Zeiss Meditec's U. 2m, representing an increase of 8. Carl Zeiss Meditec AG has resolved on a cash capital increase from authorized capital of up to 10% minus one share. Carl Zeiss Meditec AG. Apr 12, 2019 · Bloomberg the Company & Its Products Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Terminal Demo Request. , 100% of the shares in Aaren Scientific Inc. Brief profile Carl Zeiss Meditec AG: Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX of the German stock exchange, is one of the world’s leading medical technology companies. Medical technology company Carl Zeiss Meditec AG increased its revenue by 8. Get breaking news and analysis on Carl Zeiss Meditec AG (CZMWF) stock, price quote and chart, trading and investing tools. 8 percent; prior year's revenue: EUR613. Northern Florida. Carl Zeiss Meditec AG individual insider activity by MarketWatch. Das Unternehmen ist im MDAX und TecDAX der Deutschen. Standard, Custom and Semi Custom Fiber Optic components and subsystems utilizing Thin Film, AWG, Polarization, Laser and Detectors. Around 41 percent of Carl Zeiss Meditec AG’s shares are in free float. Carl Zeiss Meditec AG. Find out all the key statistics for CARL ZEISS MEDITEC AG (AFX. Otherwise you need to register using this form. 9%) compared with the same period of the prior year (prior year: EUR926. Northern Florida. Home Investor Relations Carl Zeiss Meditec Share Quotes, Charts & Orderbook Quotes, Charts & Orderbook Not all products, services or offers are approved or offered in every market and approved labelling and instructions may vary from one country to another. 9% (adjusted for currency effects: +8. Carl Zeiss Meditec is aiming for the upper end of its revenue forecast for the current year and expects strong earnings : Jena, July 15, 2019 Carl Zeiss Meditec (ISIN: DE0005313704) has achieved revenue of around EUR 1,028 million in the first nine months of fiscal year 2018/19, based on preliminary data. Contact for investors and press Sebastian Frericks Director Investor Relations Carl Zeiss Meditec AG Tel. Director Investor Relations. Pursuant to Section 161 AktG the Management and Supervisory Boards of Carl Zeiss Meditec AG are obliged to submit an annual declaration stating that the recommendations of the “Government Commission on the German Corporate Governance Code” have been complied with. Jena, 2 April. Meditec delivers innovative technologies and applications-oriented solutions that enable physicians to enhance their patients' quality of life. Carl Zeiss Meditec AG has resolved on a cash capital increase from authorized capital of up to 10% minus one share. Carl Zeiss Meditec AG has successfully completed a cash capital increase from authorized capital. & JENA, Germany--(BUSINESS WIRE)--Carl Zeiss Meditec announced today that it has received the NorthFace ScoreBoard (NFSB) Award SM from the Omega Management Group Corp. Ansprechpartner für die Presse Petra Rettenmaier Director Marketing Communications Visualization and Microsurgical Workplaces Carl Zeiss Meditec AG Tel. : +49 3641 220-116 E-Mail: investors. Die Carl Zeiss Meditec AG (ISIN: DE0005313704) hat auf Basis vorläufiger Daten innerhalb der ersten neun Monate des Geschäftsjahres 2018/19 einen Umsatz von rund 1. DGAP-News: Carl Zeiss Meditec AG / Key word(s): Product Launch25. Carl Zeiss Meditec AG. [email protected] Dazu gehören von Broker gesponsorte Konferenzen ebenso wie selbst organisierte Veranstaltungen und die Jahreshauptversammlung, die einmal jährlich stattfindet. 2016 / 07:00 The issuer is solely. Yelp is a fun and easy way to find, recommend and talk about what’s great and not so great in San Diego and beyond. They also gave news headlines about the company a news buzz of 10. To ensure the highest possible level of transparency, this website provides comprehensive and detailed information about our IR activities and the performance of Carl Zeiss Meditec. See the complete profile on LinkedIn and discover David’s connections and jobs at similar companies. Ad Hoc Announcement 18-Jul-2014. 35 percent of Carl Zeiss Meditec shares are in free float. Carl Zeiss Meditec to Acquire IanTECH, Inc. Ludwin Monz - Chief Executive Officer. Interactive share charts for Carl Zeiss Meditec AG NPV showing the latest and past performance. The capital increase announced yesterday has been successfully completed. Carl Zeiss Meditec AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution. [email protected] 9% (adjusted for currency effects: +8. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. DGAP-Media / 12. Thus, the free float will increase from 35% up to approximately 41% and thereby market liquidity of the Carl Zeiss Meditec AG share will be broadened. Christopher has 7 jobs listed on their profile. Während des gesamten Jahres nimmt Carl Zeiss Meditec AG an zahlreichen Veranstaltungen im Bereich Investor Relations teil. ZEISS presents the new IOLMaster 700 for better predictability and optimized workflows in cataract surgery The IOLMaster ® 700 with SWEPT Source Biometry™ enables physicians to identify irregular geometries of their patients eyes at an early stage. spinal, helping to prevent blindness Complete product range of microscopes for. Carl Zeiss Meditec AG (CZMWF) Investor Presentation - Slideshow. We welcome you to Carl Zeiss Meditec´s Investor Relations website and thank you for your interest in our company. Contact for investors and press Sebastian Frericks Director Investor Relations Carl Zeiss Meditec AG Tel. 9 percent (prior year: 12. Our ZEISS FORUM system with its Clinical Workplaces connects the diagnostic devices within a practice, then integrates and delivers this information from multiple modalities at the point of care - in the office and in the OR," says Jim Mazzo, Global President Ophthalmic Devices at Carl Zeiss Meditec. DUBLIN, Calif. Carl Zeiss Meditec continues strong growth trend after nine months of 2018/19. In financial year 2012/2013 (ended 30 September) the Group's more than 2,500 employees generated revenue of almost € 906 million. Carl Zeiss Meditec AG serves ophthalmologists and optometrists, as well as physicians and surgeons in hospitals and outpatient surgery centers. Sebastian Frericks is Director Investor Relations at Carl Zeiss Meditec AG. Email: investors. Carl Zeiss Meditec announced the introduction of the Humphrey(R) Matrix, the latest innovation in visual field testing and management. Mazzo to Lead Its Newly Consolidated Ophthalmology Organization Director Investor Relations Carl Zeiss Meditec AG Phone: +49 3641 220-106 Email: www. JENA, Germany & ONTARIO, Calif. The Company operates in two segments: Ophthalmic Devices and Microsurgery. 03641 220-116. Carl Zeiss Meditec continues strong. Investor Relations Contact Officer » Insider Trading. Stay alerted to dividend announcements for CZMWF and all the companies you follow at NASDAQ. 7 million After adjustment for exchange rates this corresponds to growth of 7. 9%) compared with the same period of the prior year (prior year: EUR926. Petra Rettenmaier is Former Director-Corporate Communications at Carl Zeiss Meditec AG. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. We drive the development of leading-edge technology and make it available for applications in the field of: ophthalmology, neurosurgery, ENT surgery, dental applications and systems for intraoperative radiotherapy in the treatment of breast cancer. Contact for investors and press Sebastian Frericks Director Investor Relations Carl Zeiss Meditec AG Tel. The group also. 8 million; earnings before interest and taxes (EBIT) also increased to EUR 75 million (prior year: EUR 61 million), corresponding to an EBIT margin of 13. 2019 / 07:00 The issuer is solely responsible for the content of this announcement. Carl Zeiss Meditec AG erzielt gutes Umsatz- und Ergebniswachstum in den ersten drei Monaten 2018/19 Jena, 14. See the complete profile on LinkedIn and discover Kim’s connections and jobs at similar companies. The issuer is solely responsible for the content of this announcement. Carl Zeiss Meditec AG's INTRABEAM Targeted Intraoperative Radiotherapy System Demonstrates that Single-dose Radiation is Equivalent to Prolonged Courses of Post-operative Radiation for Early Breast Cancer Treatment - read this article along with other careers information, tips and advice on BioSpace. See the complete profile on LinkedIn and discover Jeremy’s connections and jobs at similar companies. 2018 / 16:06 Carl Zeiss Meditec AG Carl Zeiss Meditec AG Announces New CFO and Expansion of the Management BoardEffective 1 October 2018,. If you want to stay up-to-date about the latest developments of Carl Zeiss Meditec. If you want to stay up-to-date about the latest developments of Carl Zeiss Meditec Group, there is no faster way. View Jann Gerrit Ohlendorf's professional profile on Relationship Science, the database of decision makers. Carl Zeiss Meditec Recruits James V. 7 percent) to EUR1,088. Strong demand for capital increase Carl Zeiss Meditec AG raises proceeds of around EUR 317 million from the capital increase. It offers offers complete solutions to diagnose and treat ophtalmic diseases, visualization solutions for. 9%) compared with the. Carl Zeiss Meditec AG. Petra Rettenmaier is Former Director-Corporate Communications at Carl Zeiss Meditec AG. The Carl Zeiss Meditec Group has operations all over the world. Director Investor Relations. Carl Zeiss Meditec AG (CZMWF) Investor Presentation - Slideshow. Over 350 of them staff the head office of Carl Zeiss Meditec AG in Jena. Carl Zeiss Meditec AG Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX and SDax of the German stock exchange, is one of the world's leading medical technology companies. Patrick Kofler Director Investor Relations. The capital increase announced yesterday has been successfully completed. : +49 3641 220-116 E-Mail: investors. footnote_1 Ansprechpartner für Investoren und Presse Sebastian Frericks Director Investor Relations Carl Zeiss Meditec AG Tel. com Brief profile Carl Zeiss Meditec AG (ISIN: DE 0005313704), the Medical Technology Business Group of ZEISS, is listed on SDAX and TecDAX of the German stock exchange and one of the world's leading medical technology companies. Investor relations; Carl Zeiss Meditec has strengthened its cataract surgical offering by acquiring an intelligent cloud-based data management platform to. Home Investor Relations Carl Zeiss Meditec Share Quotes, Charts & Orderbook Quotes, Charts & Orderbook Not all products, services or offers are approved or offered in every market and approved labelling and instructions may vary from one country to another. The issuer is solely responsible for the content of this announcement. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. [email protected] “Our comprehensive portfolio spans. Carl Zeiss Meditec AG closed fiscal year 2016/17 with solid revenue growth. DE) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives and. A total of. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. to expand its portfolio in cataract surgery : ZEISS to enhance its portfolio of Surgical Ophthalmology solutions, further positioning the Company as a global innovation leader and solution provider in the full space of ophthalmology. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their. 21 Section 1 WpHG that on 7 May 2012 the percentage of voting rights of The Royce Fund, Wilmington. The Carl-Zeiss-Stiftung (Carl Zeiss Foundation), located in Heidenheim an der Brenz and Jena, Germany, is the sole shareholder of the two companies Carl Zeiss AG and Schott AG. It operates through the Ophthalmic Devices and Microsurgery business. Carl Zeiss Meditec AG engages in the development, manufacture, and marketing of medical devices. In addition, the Carl Zeiss Meditec Group. 2018 / 06:58 The. Contact for media and investors Sebastian Frericks Director Investor Relations Carl Zeiss Meditec AG Tel. It offers offers complete solutions to diagnose and treat ophtalmic diseases, visualization solutions for. “At ZEISS, we are committed to advance eye care by connecting the patient data every step of the way,” says Dr. Carl Zeiss introduces a new, minimally invasive technique for the correction of refractive errors and sets another milestone in refractive corneal surgery. Carl Zeiss Meditec is aiming for the upper end of its revenue forecast for the current year and expects strong earnings : Jena, July 15, 2019 Carl Zeiss Meditec (ISIN: DE0005313704) has achieved. In financial year 2012/2013 (ended 30 September) the Group's more than 2,500 employees generated revenue of almost € 906 million. Während des gesamten Jahres nimmt Carl Zeiss Meditec AG an zahlreichen Veranstaltungen im Bereich Investor Relations teil. Carl Zeiss Meditec Recruits James V. DOW JONES, A NEWS CORP COMPANY News Corp is a network of leading companies in the worlds of diversified media, news, education, and information services. Brief profile Carl Zeiss Meditec AG: Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX of the German stock exchange, is one of the world's leading medical technology companies. Director Investor Relations Carl Zeiss Meditec AG Phone: +49 3641 220-116 Fax: investors. com Brief profile Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on MDAX and TecDax of the German stock exchange, is one of the world's leading medical technology companies. ZEISS Medical. Carl Zeiss-Stand auf der IDS: Halle 10. 2014] Carl Zeiss Meditec AG und PhysIOL SA legen Rechtsstreit bei PhysIOL SA und Carl Zeiss Meditec AG haben sich außergerichtlich darauf verständigt, einen Rechtsstreit um Patente und Gebrauchsmuster für trifokale Intraokularlinsen (IOL) beizulegen. Schallhorn, MD as Chief Medical Officer for Global Ophthalmic Devices consisting. Carl Zeiss Meditec AG / / Ad hoc: Carl Zeiss Meditec continues successful growth strategy with new Chief Executive Officer processed and transmitted by Hugin AS. The order book was closed early thanks to the strong demand. These are the archived documents that have been published in connection with Investor Relations within the last years. 7m (prior year. He also oversees Service, Quality Management and Regulatory Affairs. The New Humphrey Field Analyzer 3 From ZEISS Sets a New Standard for Efficient Visual Field Testing for investors: Carl Zeiss Meditec AG a New Standard for Efficient Visual Field Testing. E-Mail: investors. Carl Zeiss Meditec is aiming for the upper end of its revenue forecast for the current year and expects strong earnings : Jena, July 15, 2019 Carl Zeiss Meditec (ISIN: DE0005313704) has achieved. Don’t miss John Carlson moderating a panel on “The Future of Partnerships with the Influx of Non-Traditional Players & Disruptive Technologies” on Oct. Tec GmbH in Carl Zeiss Meditec's reporting entity. Carl Zeiss Meditec AG closed fiscal year 2016/17 with solid revenue growth. , 100% of the shares in Aaren Scientific Inc. He also oversees Service, Quality Management and Regulatory Affairs. The medical technology portfolio of Carl Zeiss Meditec is rounded off by promising, future-oriented technologies such as intraoperative radiotherapy. 22 hours ago · Investor Relations Bellevue Asset Management AG Seestrasse 16, 8700 Küsnacht, Schweiz Tel. In the first nine months of financial year 2013/2014 medical technology company Carl Zeiss Meditec AG increased its revenue to € 673. “At ZEISS, we are committed to advance eye care by connecting the patient data every step of the way,” says Dr. Carl Zeiss Meditec is aiming for the upper end of its revenue forecast for the current year and expects strong earnings : Jena, July 15, 2019 Carl Zeiss Meditec (ISIN: DE0005313704) has achieved. They also gave news headlines about the company a news buzz of 10. Investor Relations We welcome you to Carl Zeiss Meditec´s Investor Relations website and thank you for your interest in our company. In Germany, Carl Zeiss Meditec generated consolidated revenue of EUR 38. Carl Zeiss Meditec generated revenue of EUR1,027. The Company supplies innovative technologies and. in recognition of achieving excellence in customer service in. Based in Silicon Valley area, working on various research and development projects for future ADAS functions to become real soon in autonomous and pre-development cars (validating parking pilot, highway pilot, traffic jam pilot, hands-off driving, summons). It operates through the Ophthalmic Devices and Microsurgery business segments. Carl Zeiss Meditec, the medical technology arm of German optical and opto-electronics group Carl Zeiss, has appointed Ludwin Monz as its new CEO. Carl Zeiss Meditec reports revenue growth of 3. Description: Carl Zeiss Meditec AG is a Jena, Germany-based manufacturer of ophthalmic devices, such as intraocular lenses, diagnostic equipment, and refractive laser systems, along with optical equipment for microsurgical applications such as neurosurgery. : +49 3641 220-106. [email protected] Search Carl Zeiss Meditec IT job opportunities in Dublin, California. Carl Zeiss Meditec weiter profitabel gewachsen Erfolgreiches erstes Halbjahr - Das Unternehmen. 00 and the low price target for AFX is €58. Latest stock price today and the US's most active stock market forums. 9% (adjusted for currency effects: +8. Ansprechpartner für Investoren und Presse Sebastian Frericks Director Investor Relations Carl Zeiss Meditec AG Tel. Your Personal Contact. The issuer is solely responsible for the content of this announcement. 7 percent) to EUR1,088. Carl Zeiss-Stand auf der IDS: Halle 10. The group also. Carl Zeiss Meditec AG est l'un fournisseurs de premier ordre dans le domaine de la technologie médicale. Carl Zeiss Meditec to acquire Laser Diagnostic Technologies Acquisition complements product portfolio and makes Carl Zeiss Meditec the undisputed market leader in the growth market of glaucoma diagnosis and management Dublin, CA - Jena, Germany, October 21, 2004 – Carl Zeiss Meditec, Inc. View News Stories for Carl Zeiss Meditec. It offers offers complete solutions to diagnose and treat ophtalmic diseases, visualization solutions for microsurgery and other technologies, such as intraoperative radiotherapy. A total of. Mazzo will join Carl Zeiss Meditec as Global President of Ophthalmology with responsibility for the new Strategic Business Unit Ophthalmology as well as Carl Zeiss Meditec's U. Wir möchten den Ärzten daher von Anfang an Diagnoselösungen anbieten, die verlässlich und effizient alle wichtigen Untersuchungsergebnisse in ZEISS Qualität liefern", sagt Dr. 7 million After adjustment for exchange rates this corresponds to growth of 7. Der Vorstand legte den Aktionären die Bilanz für das Geschäftsjahr 2017/18 vor, das bis Ende September lief. Ludwin Monz, President and CEO of Carl Zeiss Meditec. Nachrichten zu Carl Zeiss Meditec Carl Zeiss Meditec » DGAP-PVR: Carl Zeiss Meditec AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the. meditec @ zeiss. Ich stimme einer elektronischen Speicherung und Verarbeitung meiner eingegebenen Daten zur Beantwortung meiner Anfrage zu. For more information, please go to: www. DGAP Voting Rights Announcement: Carl Zeiss Meditec AG Carl Zeiss Meditec AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of. at MPO Summit 2019. Head of Investor Relations Carl Zeiss Meditec AG. comAsia PacificLevel 462 Park StreetSydney,. The Ophthalmic Devices segment includes intraocular lenses, surgical visualization solutions, and medical laser and diagnostic systems. Around 41 percent of Carl Zeiss Meditec AG's shares are in free float. The issuer is solely responsible for the content of this announcement. Apr 12, 2019 · Bloomberg the Company & Its Products Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Terminal Demo Request. Carl Zeiss Meditec AG resolves on a cash capital increase of up to 10 percent. Dependent company report Given that Carl Zeiss Meditec AG is a company within Carl Zeiss AG, the Management Board of Carl Zeiss Meditec AG prepared a report, pursuant to Section 312 AktG, on relations with associated companies in nancial year 2013/2014, which states that under the circumstances known to the Management Board at the time the. com [1] Currency-adjusted sales growth is determined by weighting sales in the comparative period with current instead of actual historical exchange rates. ReLEx smile - Flapless Laser Treatments with Femtosecond Laser from Carl Zeiss for the First Time. "ZEISS has set the pace in digital advancements, collaborating with leading doctors and scientists around the world with integrated, data-driven solutions," says Dr. The Management Board and Supervisory Board of Carl Zeiss Meditec AG hereby declare, pursuant to Section 161 (1) Sentence 1 AktG, that since issuing its last Declaration of Conformity on 7 December 2017, Carl Zeiss Meditec AG has conformed and does conform to all recommendations of the Government Commission on the German Corporate Governance Code, as published by the German Federal Ministry of. Assistentin Investor Relations bei Carl Zeiss Meditec AG Jena, Thuringia, Germany Medical Devices. Monday, December 14, 2009 12:27 AM JENA, Germany—Dr. Managing the Medical Division on the Italian subsidiary, developing and executing the company’s strategies, controlling and overseeing Sales, Marketing and Service operations, people and ventures. The medical technology portfolio of Carl Zeiss Meditec is rounded off by promising, future-oriented technologies such as intraoperative radiotherapy. The head office of Carl Zeiss Meditec is in Jena, Germany. [email protected] ZEISS Medical Technology on the Social Web Director Investor Relations press. Carl Zeiss Meditec Recruits James V. DGAP-Ad-hoc: Carl Zeiss Meditec AG / Key word(s): Preliminary Results/Quarter Results Carl Zeiss Meditec AG acieves strong revenue and EBIT growth in first three months 2018/19 14-Jan-2019 / 15:47. E-Mail: investors. 2017 / 07:00 Für den Inhalt der Mitteilung ist der | 8 Dezember 2017. This section delivers all relevant material related to Carl Zeiss Meditec´s financial subjects. In financial year 2012/2013 (ended 30 September) the Group's more than 2,500 employees generated revenue of almost € 906 million. the Carl Zeiss Innovation Center for Research and Development in Shanghai, China, strengthen the company's presence in these fast -growing countries. Director Investor Relations. Carl Zeiss Meditec earned a news sentiment score of 1. EBIT margin rose further year-on-year. (Thomson Reuters ONE via COMTEX) -- Carl Zeiss Meditec AG / Carl Zeiss Meditec AG : Carl Zeiss Meditec improves its results in first six months of financial year 2012/2013. The issuer is solely responsible for the content of this announcement. Wir liefern Innovative Technologien und applikationsorientierte Lösungen, die es den Ärzten ermöglichen, die Lebensqualität ihrer Patienten zu verbessern. DGAP-Adhoc: Carl Zeiss Meditec is aiming for the upper end of its revenue forecast for the current year and expects strong earnings. Around 41 percent of Carl Zeiss Meditec AG’s shares are in free float. Investor Relations Contact Officer » Insider Trading. Nachrichten zu Carl Zeiss Meditec Carl Zeiss Meditec » DGAP-PVR: Carl Zeiss Meditec AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the. Carl Zeiss Meditec Vertriebsgesellschaft mbH in Jena, reviews by real people. Carl Zeiss Meditec AG / Key word(s): Capital Increase/Corporate Action22-March-2017 / 08:12 CET/CESTDisclosure of an inside information acc. Ludwin Monz becomes CEO of Carl Zeiss Meditec processed and transmitted by Hugin AS. Carl Zeiss Meditec AG ist eines der führenden Medizintechnikunternehmen weltweit. Search Carl Zeiss Meditec jobs in Minneapolis, Minnesota. DGAP-News: Carl Zeiss Meditec AG / Key word(s): Quarterly / Interim Statement/Quarter Results Carl Zeiss Meditec AG starts new fiscal year 2017/18 with solid revenue growth 12. View profile. Carl Zeiss Meditec to Acquire IanTECH, Inc. CARL-ZEISS MEDITEC Aktie (ISIN DE0005313704 / WKN 531370). JENA, 9 August 2019. , 100% of the shares in Aaren Scientific Inc. The issuer is. Carl Zeiss Meditec AG, which is listed on TecDAX of the German stock exchange, is one of the world's leading medical technology companies. Kontakt: Carl Zeiss Meditec AG, Jens Brajer/Director Investor Relations, Göschwitzer Str. Carl Zeiss Meditec, Live Indikation, Chart, Kurs, Statistiken, wikifolio, Social Media, Trading, Bilder (ISIN: DE0005313704). JENA - 18 January 2010. DUBLIN, Calif. Our ZEISS FORUM system with its Clinical Workplaces connects the diagnostic devices within a practice, then integrates and delivers this information from multiple modalities at the point of care - in the office and in the OR," says Jim Mazzo, Global President Ophthalmic Devices at Carl Zeiss Meditec. It operates through the Ophthalmic Devices and Microsurgery business segments. 22 hours ago · Investor Relations Bellevue Asset Management AG Seestrasse 16, 8700 Küsnacht, Schweiz Tel. 65% are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries. 7 percent (adjusted for currency effects: +6. 3 percent; at the end of the day, considering the significant negative impact from currency translation effects which were also present in previous quarters, revenue lifted by 3. Carl Zeiss Meditec September 2006 – Present 13 years 1 month. Meditec delivers innovative technologies and applications-oriented solutions that enable physicians to enhance their patients' quality of life. Erfahren Sie mehr über die Kontakte von Clara Kries und über Jobs bei ähnlichen Unternehmen. Corporate governance. Carl Zeiss Meditec AG. Home _Trash Investor Relations IR Calendar and Events Annual General Meeting Annual General Meeting 2013 The Annual General Meeting of Carl Zeiss Meditec AG for the financial year 2011/2012 was held on 5 March 2013 in the congress centrum neue weimarhalle in Weimar. Key Personnel: Michael Kaschke, president & CEO; Thomas Spitzenpfeil, CFO; Matthias Metz, president & CEO, Carl Zeiss Vision International; Ludwin Monz, president. [email protected] Sehen Sie sich das Profil von Clara Kries auf LinkedIn an, dem weltweit größten beruflichen Netzwerk. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. 9% (adjusted for currency effects: +8. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their. View the latest news on CZMWF company insiders for their impact on company performance. The company now reports in two primary segments, ophthalmic devices (73% of fiscal 2018.